(Q50042810)

English

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.

scientific article published on 11 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

0 references

1 reference

based on heuristic

inferred from title

author name string

Kaichao Feng

1

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Yelei Guo

2

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Hanren Dai

3

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Yao Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Xiang Li

5

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Hejin Jia

6

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Weidong Han

7

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

publication date

11 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

Science in China. Series C: Life Sciences

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

59

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

5

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

468-479

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

https://scigraph.springernature.com/pub.10.1007/s11427-016-5023-8

0 references

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Chemotherapeutic targeting of cancer-induced immunosuppressive cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

NK cell-based cancer immunotherapy: from basic biology to clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1007%2FS11427-016-5023-8

21 January 2018

Identifiers

10.1007/S11427-016-5023-8

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 February 2018

http://europepmc.org/abstract/MED/26968708

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50042810&oldid=1297085181"